Nanox Announces Third Quarter of 2025 Financial Results and Provides Business Update
Rhea-AI Summary
Nanox (NASDAQ:NNOX) reported third-quarter 2025 results and a business update on November 20, 2025. The company generated $3.4M revenue in Q3 2025 versus $3.0M year-ago, and reported a GAAP net loss of $13.7M for the quarter. Gross loss was $2.9M (GAAP) and non-GAAP gross loss was $0.3M. Nanox completed the acquisition of Vaso Healthcare IT, added clinical sites including Cedars-Sinai and Olympe Imagerie, and signed European ARC distribution partnerships. Cash and equivalents totaled $55.5M as of September 30, 2025, and the company expects >100 deployed units by year-end 2025 and $35M revenue for 2026.
Positive
- Revenue increased to $3.4M in Q3 2025
- Acquisition of Vaso Healthcare IT completed
- Added clinical sites including Cedars-Sinai and Olympe Imagerie
- Guidance of $35M revenue for 2026
Negative
- GAAP net loss of $13.7M in Q3 2025
- Cash and equivalents down to $55.5M from $83.2M
- Negative operating cash flow of $30.4M year-to-date
News Market Reaction – NNOX
In the Nov 20 session, NNOX gained 13.86%, reflecting a significant positive market reaction. Argus tracked a peak move of +33.0% during that session. Our momentum scanner triggered 63 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 6.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET
Company advances commercialization and is on track to meet year-end system deployment target
PETAH TIKVA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2025, and provided a business update.
Recent Highlights:
- Generated
$3.4 million in revenue in the third quarter of 2025, compared to$3.0 million in the third quarter of 2024. - Acquired
100% of the stock of Vaso Healthcare IT, a provider of healthcare information technologies solutions, for cash and future operational based earnouts. - Secured new commercial collaborations to accelerate commercialization of the Nanox.ARC and AI Solutions globally.
- Advanced clinical work supporting the use of Nanox solutions and adding Cedars-Sinai in Los Angeles and Olympe Imagerie in Paris as clinical trial sites.
- Made inroads into the European market, signing ARC distribution partnerships with EXRAY, a Czech imaging equipment distributor, and Althea France SARL, one of Europe’s largest independent providers of medical technology services.
“We made a significant progress across our three strategic growth pillars in the third quarter. These pillars focus on advancing Nanox technologies and market expansion, continuing to build out our AI infrastructure, and doing all of this with improved operational efficiency,” said Erez Meltzer, Nanox Chief Executive Officer and Acting Chairman of the Board. “During the quarter, we entered into multiple collaborations around the world to advance commercialization of both the Nanox.ARC and AI solutions, capped by the acquisition of Vaso Healthcare IT which aims to enlarge our growing AI solutions business. Our organization is focused on execution and is well-positioned to build on our momentum in the coming years.”
Financial results for three months ended September 30, 2025
For the three months ended September 30, 2025 (the “Reported Period”), the Company reported a net loss of
The Company reported revenue of
The Company’s gross loss during the Reported Period totaled
The Company’s revenue from teleradiology services for the Reported Period was
During the Reported Period, the Company generated revenue through the sales and deployment of its imaging systems and OEM services which amounted to
The Company’s revenue from its AI solutions for the Reported Period was
Research and development expenses, net of grants received, for the Reported Period were
Sales and marketing expenses for the Reported Period were
General and administrative expenses for the Reported Period were
Non-GAAP net loss attributable to ordinary shares for the Reported Period was
Non-GAAP gross loss for the Reported Period was
The difference between the GAAP and non-GAAP financial measures above is mainly attributable to amortization of intangible assets, share-based compensation, expenses related to an offering and legal fees in connection with the class-action litigation. A reconciliation between GAAP and non-GAAP financial measures for the three and nine months periods ended September 30, 2025, and 2024 is provided in the financial results that are part of this press release.
Limited Guidance
Based on current market conditions and assuming that macroeconomic trends, including tariff policy, inflation, interest rate levels and supply chain costs do not materially impede activity in the medical technology industry generally, or for the Company specifically, the Company anticipates that the number of clinical, demo, and commercial units in various stages of deployment will grow to over 100 units by the end of 2025, on a worldwide basis.
2026 Full-Year Guidance
The guidance that follows supersedes all prior financial guidance or outlook statements made by the Company, constitutes forward-looking information within the meaning of applicable securities laws, and is based on a number of assumptions and subject to a number of risks. Actual results could vary materially as a result of numerous factors, including certain known and unknown uncertainties and risks factors, many of which are beyond the Company’s control. Please see “Forward-Looking Statements” below for more information.
- For the year 2026 we expect revenues to reach
$35 million .
Liquidity and Capital Resources
As of September 30, 2025, the Company had total cash, cash equivalents, short-term and long-term deposits and marketable securities of
Other Assets
As of September, 30, 2025 the Company had property and equipment of
As of September 30, 2025, the Company had intangible assets of
Shareholders’ Equity
As of September 30, 2025 the Company had approximately 65.4 million shares outstanding compared to 63.8 million shares outstanding as of December 31, 2024. During the third quarter of 2025, the Company sold approximately 1.4 million ordinary shares, which generated net proceeds of approximately
Conference Call and Webcast Details
Thursday, November 20, 2025 @ 8:30am ET
Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Nanox website under Events & Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.
About Nanox:
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.
Nanox’s vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases, through Nanox’s subsidiary, Nanox.AI Ltd; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision
Forward-Looking Statements
This press release may contain forward-looking statements and forward-looking information (collectively, the “forward-looking statements”), that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to: guidance with respect to the number of units that the Company will have deployed by the end of the 2025 year the Company’s financial outlook, including expected revenue for the next fiscal year; the ability to successfully integrate VHC IT following the acquisition as well as to improve deployment speed pace and implementation quality; the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC; and the ability of the Company to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of its recent acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks relating to macroeconomic factors, including tariff policy, inflation, interest rate levels and supply chain costs; and (xi) potential litigation associated with our transactions; (xii) the Company’s ability to maintain expected growth and manage expenses.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. The forward-looking statements are provided to give additional information about management’s expectations and beliefs and may not be appropriate for other purposes. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses and non-GAAP basic and diluted loss per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, expenses relating to an offering and legal fees in connection with class-action litigation. The Company’s management and board of directors utilize these non-GAAP financial measures to evaluate the Company’s performance. The Company provides these non-GAAP measures of the Company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, these non-GAAP measures should not be considered measures of the Company’s liquidity. A reconciliation of certain GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Investors
Mike Cavanaugh
ICR Healthcare
Mike.cavanaugh@icrhealthcare.com
Media
ICR Healthcare
NanoxPR@icrinc.com
| NANO-X IMAGING LTD. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands except share and per share data) | ||||||||
| September 30, 2025 | December 31, 2024 | |||||||
| U.S. Dollars in thousands | ||||||||
| Assets | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | 45,186 | 39,304 | ||||||
| Short-term deposits | - | 15,500 | ||||||
| Marketable securities | - | 18,402 | ||||||
| Accounts receivables net of allowance for credit losses of | 1,937 | 1,805 | ||||||
| Inventories | 2,668 | 1,493 | ||||||
| Prepaid expenses | 783 | 827 | ||||||
| Other current assets | 739 | 1,349 | ||||||
| TOTAL CURRENT ASSETS | 51,313 | 78,680 | ||||||
| NON-CURRENT ASSETS: | ||||||||
| Restricted deposit | 373 | 337 | ||||||
| Long-term deposits | 10,354 | 10,000 | ||||||
| Property and equipment, net | 46,753 | 45,355 | ||||||
| Operating lease right-of-use asset | 3,635 | 3,843 | ||||||
| Intangible assets | 62,036 | 69,995 | ||||||
| Other non-current assets | 1,623 | 1,792 | ||||||
| TOTAL NON-CURRENT ASSETS | 124,774 | 131,322 | ||||||
| TOTAL ASSETS | 176,087 | 210,002 | ||||||
| Liabilities and Shareholders’ Equity | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Short-term loan | 3,209 | 3,061 | ||||||
| Accounts payable | 1,412 | 2,209 | ||||||
| Accrued expenses | 2,298 | 3,968 | ||||||
| Deferred revenue | 273 | 140 | ||||||
| Current maturities of operating lease liabilities | 935 | 745 | ||||||
| Other current liabilities | 4,262 | 3,849 | ||||||
| TOTAL CURRENT LIABILITIES | 12,389 | 13,972 | ||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Non-current operating lease liabilities | 3,735 | 3,640 | ||||||
| Deferred tax liability | 2,293 | 2,576 | ||||||
| Other long-term liabilities | 961 | 695 | ||||||
| TOTAL NON-CURRENT LIABILITIES | 6,989 | 6,911 | ||||||
| TOTAL LIABILITIES | 19,378 | 20,883 | ||||||
| COMMITMENTS AND CONTINGENCIES (Note 3) | ||||||||
| SHAREHOLDERS’ EQUITY: | ||||||||
| Ordinary Shares, par value NIS 0.01 per share 100,000,000 authorized at September 30, 2025 and December 31, 2024, 65,382,892 and 63,762,001 issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 185 | 181 | ||||||
| Additional paid-in capital | 571,918 | 562,688 | ||||||
| Accumulated other comprehensive loss | - | (1 | ) | |||||
| Accumulated deficit | (415,394 | ) | (373,749 | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY | 156,709 | 189,119 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 176,087 | 210,002 | ||||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements | ||||||||
| NANO-X IMAGING LTD. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (U.S. dollars in thousands except share and per share data) | ||||||||||||||||
| Nine Months Ended September 30, | Three Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| REVENUE | 9,302 | 8,283 | 3,447 | 3,031 | ||||||||||||
| COST OF REVENUE | 18,473 | 16,002 | 6,329 | 5,843 | ||||||||||||
| GROSS LOSS | (9,171 | ) | (7,719 | ) | (2,882 | ) | (2,812 | ) | ||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and development, net | 14,398 | 14,781 | 4,586 | 4,749 | ||||||||||||
| Sales and marketing | 3,666 | 2,521 | 1,488 | 887 | ||||||||||||
| General and administrative | 15,541 | 16,669 | 5,276 | 5,711 | ||||||||||||
| Other expenses (income), net | 40 | 81 | 3 | (20 | ) | |||||||||||
| TOTAL OPERATING EXPENSES | 33,645 | 34,052 | 11,353 | 11,327 | ||||||||||||
| OPERATING LOSS | (42,816 | ) | (41,771 | ) | (14,235 | ) | (14,139 | ) | ||||||||
| REALIZED INCOME (LOSS) FROM SALE OF MARKETABLE SECURITIES | - | 2 | - | 2 | ||||||||||||
| FINANCIAL INCOME, net | 1,073 | 2,050 | 457 | 404 | ||||||||||||
| OPERATING LOSS BEFORE INCOME TAXES | (41,743 | ) | (39,719 | ) | (13,778 | ) | (13,733 | ) | ||||||||
| INCOME TAX BENEFIT | 98 | 264 | 94 | 94 | ||||||||||||
| NET LOSS | (41,645 | ) | (39,455 | ) | (13,684 | ) | (13,639 | ) | ||||||||
| BASIC AND DILUTED LOSS PER SHARE | (0.65 | ) | (0.68 | ) | (0.21 | ) | (0.23 | ) | ||||||||
| Weighted average number of basic and diluted ordinary shares outstanding (in thousands) | 64,025 | 58,182 | 64,324 | 58,624 | ||||||||||||
| Net Loss | (41,645 | ) | (39,455 | ) | (13,684 | ) | (13,639 | ) | ||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Reclassification of net income realized in income statement | - | (2 | ) | - | (2 | ) | ||||||||||
| Unrealized gain (loss) from marketable securities | 1 | 319 | (1 | ) | 66 | |||||||||||
| Total other comprehensive income (loss): | 1 | 317 | (1 | ) | 64 | |||||||||||
| Total comprehensive loss | (41,644 | ) | (39,138 | ) | (13,685 | ) | (13,575 | ) | ||||||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements | ||||||||||||||||
| NANO-X IMAGING LTD. UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (U.S. dollars in thousands, except share and per share data) | ||||||||||||||||||||||||
| Ordinary shares | Additional | Accumulated other | ||||||||||||||||||||||
| Number of shares | Amount | paid-in capital | comprehensive loss | Accumulated deficit | Total | |||||||||||||||||||
| U.S. Dollars in thousands | ||||||||||||||||||||||||
| BALANCE AT JANUARY 1, 2025 | 63,762,001 | 181 | 562,688 | (1 | ) | (373,749 | ) | 189,119 | ||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares, net of issuance expenses ** | 1,420,903 | 4 | 5,691 | - | - | 5,695 | ||||||||||||||||||
| Issuance of ordinary shares upon exercise of RSUs | 9,735 | * | - | - | - | - | ||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 74,027 | * | 163 | - | - | 163 | ||||||||||||||||||
| Issuance of ordinary shares due the settlement of contingent earnout | 116,226 | * | - | - | - | * | ||||||||||||||||||
| Share-based compensation | - | - | 3,376 | - | - | 3,376 | ||||||||||||||||||
| Unrealized gain from marketable securities | - | - | - | 1 | - | 1 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (41,645 | ) | (41,645 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2025 | 65,382,892 | 185 | 571,918 | - | (415,394 | ) | 156,709 | |||||||||||||||||
| * | Less than |
| ** | Issuance expenses totaled to |
| Ordinary shares | Additional | Accumulated other | ||||||||||||||||||||||
| Number of shares | Amount | paid-in capital | comprehensive loss | Accumulated deficit | Total | |||||||||||||||||||
| BALANCE AT JANUARY 1, 2024 | 57,778,628 | 165 | 515,887 | (305 | ) | (320,233 | ) | 195,514 | ||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 743,306 | 2 | 1,664 | - | - | 1,666 | ||||||||||||||||||
| Share-based compensation | - | - | 5,845 | - | - | 5,845 | ||||||||||||||||||
| Unrealized gain from marketable securities | - | - | - | 317 | - | 317 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (39,455 | ) | (39,455 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2024 | 58,521,934 | 167 | 523,396 | 12 | (359,688 | ) | 163,887 | |||||||||||||||||
| Accumulated | ||||||||||||||||||||||||
| Ordinary shares | Additional | other | ||||||||||||||||||||||
| Number of | paid-in | comprehensive | Accumulated | |||||||||||||||||||||
| shares | Amount | capital | deficit | deficit | Total | |||||||||||||||||||
| U.S. Dollars in thousands | ||||||||||||||||||||||||
| BALANCE AT JULY 1, 2025 | 63,939,620 | 181 | 565,086 | 1 | (401,710 | ) | 163,558 | |||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares, net of issuance expenses ** | 1,420,903 | 4 | 5,691 | - | - | 5,695 | ||||||||||||||||||
| Issuance of ordinary shares upon exercise of RSUs | 3,245 | * | - | - | - | - | ||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 19,124 | * | 42 | - | - | 42 | ||||||||||||||||||
| Unrealized (loss) from marketable securities | - | - | - | (1 | ) | - | (1 | ) | ||||||||||||||||
| Share-based compensation | - | - | 1,099 | - | - | 1,099 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (13,684 | ) | (13,684 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2025 | 65,382,892 | 185 | 571,918 | - | (415,394 | ) | 156,709 | |||||||||||||||||
| * | Less than |
| ** | Issuance expenses totaled to |
| Accumulated | ||||||||||||||||||||||||
| Ordinary shares | Additional | other | ||||||||||||||||||||||
| Number of | paid-in | comprehensive | Accumulated | |||||||||||||||||||||
| shares | Amount | capital | deficit | deficit | Total | |||||||||||||||||||
| U.S. Dollars in thousands | ||||||||||||||||||||||||
| BALANCE AT JULY 1, 2024 | 58,497,123 | 167 | 521,069 | (52 | ) | (346,049 | ) | 175,135 | ||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 24,811 | * | 60 | - | - | 60 | ||||||||||||||||||
| Other comprehensive gain | - | - | - | 64 | - | 64 | ||||||||||||||||||
| Share-based compensation | - | - | 2,267 | - | - | 2,267 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (13,639 | ) | (13,639 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2024 | 58,521,934 | 167 | 523,396 | 12 | (359,688 | ) | 163,887 | |||||||||||||||||
| * | Less than |
| NANO-X IMAGING LTD. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in thousands) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss for the period | (41,645 | ) | (39,455 | ) | ||||
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
| Share-based compensation | 3,376 | 5,845 | ||||||
| Amortization of intangible assets | 7,959 | 7,959 | ||||||
| Exchange rate differentials | 186 | (108 | ) | |||||
| Depreciation | 891 | 839 | ||||||
| Deferred tax liability, net | (283 | ) | (283 | ) | ||||
| Realized income from sale of marketable securities | - | (2 | ) | |||||
| Amortization of premium, discount and accrued interest on marketable securities | 108 | (113 | ) | |||||
| Interest on long-term deposits | (354 | ) | - | |||||
| Loss from disposal of property and equipment | 71 | 116 | ||||||
| Changes in Operating Assets and Liabilities: | ||||||||
| Accounts receivable | (132 | ) | (8 | ) | ||||
| Change in inventories | (23 | ) | (140 | ) | ||||
| Prepaid expenses and other current assets | 654 | 1,206 | ||||||
| Other non-current assets | 30 | 183 | ||||||
| Accounts payable | (852 | ) | (1,972 | ) | ||||
| Operating lease assets and liabilities | 493 | 104 | ||||||
| Accrued expenses and other liabilities | (1,257 | ) | (74 | ) | ||||
| Deferred Revenue | 133 | (246 | ) | |||||
| Other long-term liabilities | 266 | 83 | ||||||
| Net cash used in operating activities | (30,379 | ) | (26,066 | ) | ||||
| CASH FLOWS PROVIDED BY INVESTING ACTIVITIES: | ||||||||
| Purchase of property and equipment | (3,319 | ) | (1,730 | ) | ||||
| Short-term deposits | 15,500 | - | ||||||
| Purchase of marketable securities | - | (33,017 | ) | |||||
| Proceeds from maturity of marketable securities | 18,295 | 40,938 | ||||||
| Net cash provided by investing activities | 30,476 | 6,191 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of ordinary shares, net of issuance costs | 5,695 | - | ||||||
| Proceeds from issuance of ordinary shares upon exercise of options | 163 | 1,666 | ||||||
| Net cash provided by financing activities | 5,858 | 1,666 | ||||||
| EFFECT OF CHANGES IN EXCHANGE RATES ON CASH AND CASH EQUIVALENTS | (73 | ) | 25 | |||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 5,882 | (18,184 | ) | |||||
| CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD | 39,304 | 56,377 | ||||||
| CASH AND CASH EQUIVALENTS AT END OF THE PERIOD | 45,186 | 38,193 | ||||||
| SUPPLEMENTARY INFORMATION ON ACTIVITIES INVOLVING CASH FLOWS | ||||||||
| Cash paid for interest | 103 | 106 | ||||||
| Cash paid for income taxes | 184 | 51 | ||||||
| SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS - | ||||||||
| Operating lease liabilities arising from obtaining operating right-of use assets | 131 | - | ||||||
| Non-cash purchase of property and equipment | 54 | - | ||||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements | ||||||||
| UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS | |
| (U.S. dollars in thousands (except per share data)) | |
Use of Non-GAAP Financial Measures
The unaudited condensed consolidated financial information is prepared in conformity with GAAP. The Company uses information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit (loss), non-GAAP gross profit (loss) margin, non-GAAP research and development expenses, net, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other expenses (income) and non-GAAP basic and diluted loss per share. These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, expenses related to an offering and legal fees expenses in connection with class-action litigation. The Company believes that separate analysis and exclusion of the one-off or non-cash impact of the above reconciling items (as applicable) adds clarity to the constituent parts of its performance. The Company reviews these non-GAAP financial measures together with GAAP financial measures to obtain a better understanding of its operating performance. It uses the non-GAAP financial measures for planning, forecasting, and measuring results against the forecast. The Company believes that the non-GAAP financial measures are useful supplemental information for investors and analysts to assess its operating performance. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance.
Reconciliation of GAAP net loss attributable to ordinary shares to Non-GAAP net loss attributable to ordinary shares and Non-GAAP basic and diluted loss per share (U.S. dollars in thousands)
| Nine Months Ended | Three Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| GAAP net loss attributable to ordinary shares | 41,645 | 39,455 | 13,684 | 13,639 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Less: Class-action litigation and SEC investigation | 33 | 76 | - | - | ||||||||||||
| Less: Amortization of intangible assets | 7,959 | 7,959 | 2,653 | 2,653 | ||||||||||||
| Less: Offering expenses | - | 420 | - | - | ||||||||||||
| Less: Share-based compensation | 3,376 | 5,845 | 1,099 | 2,267 | ||||||||||||
| Non-GAAP net loss attributable to ordinary shares | 30,277 | 25,155 | 9,932 | 8,719 | ||||||||||||
| BASIC AND DILUTED LOSS PER SHARE | 0.47 | 0.43 | 0.15 | 0.15 | ||||||||||||
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES (in thousands) | 64,025 | 58,182 | 64,324 | 58,624 | ||||||||||||
Reconciliation of GAAP cost of revenue to Non-GAAP cost of revenue (U.S. dollars in thousands)
| GAAP cost of revenue | 18,473 | 16,002 | 6,329 | 5,843 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 7,668 | 7,668 | 2,556 | 2,556 | ||||||||||||
| Share-based compensation | 143 | 173 | 37 | 61 | ||||||||||||
| Non-GAAP cost of revenue | 10,662 | 8,161 | 3,736 | 3,226 | ||||||||||||
Reconciliation of GAAP gross loss to Non-GAAP gross profit (U.S. dollars in thousands)
| GAAP gross loss | (9,171 | ) | (7,719 | ) | (2,882 | ) | (2,812 | ) | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 7,668 | 7,668 | 2,556 | 2,556 | ||||||||||||
| Share-based compensation | 143 | 173 | 37 | 61 | ||||||||||||
| Non-GAAP gross profit (loss) | (1,360 | ) | 122 | (289 | ) | (195 | ) | |||||||||
Reconciliation of GAAP gross loss margin to Non-GAAP gross profit margin (in percentage of revenue)
| GAAP gross loss margin | (99 | )% | (93 | )% | (84 | )% | (93 | )% | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 82 | % | 92 | % | 75 | % | 85 | % | ||||||||
| Share-based compensation | 2 | % | 2 | % | 1 | % | 2 | % | ||||||||
| Non-GAAP gross profit (loss) margin | (15 | )% | 1 | % | (8 | )% | (6 | )% | ||||||||
Reconciliation of GAAP research and development, expenses to Non-GAAP research and development expenses, net (U.S. dollars in thousands)
| GAAP research and development expenses, net | 14,398 | 14,781 | 4,586 | 4,749 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Share-based compensation | 1,015 | 2,039 | 323 | 723 | ||||||||||||
| Non-GAAP research and development expenses, net | 13,383 | 12,742 | 4,263 | 4,026 | ||||||||||||
Reconciliation of GAAP sales and marketing expenses to Non-GAAP sales and marketing expenses (U.S. dollars in thousands)
| GAAP sales and marketing expenses | 3,666 | 2,521 | 1,488 | 887 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 291 | 291 | 97 | 97 | ||||||||||||
| Share-based compensation | 263 | 572 | 91 | 222 | ||||||||||||
| Non-GAAP sales and marketing expenses | 3,112 | 1,658 | 1,300 | 568 | ||||||||||||
Reconciliation of GAAP general and administrative expenses to Non-GAAP general and administrative expenses (U.S. dollars in thousands)
| GAAP general and administrative expenses | 15,541 | 16,669 | 5,276 | 5,711 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Class-action litigation and SEC investigation | 33 | 76 | - | - | ||||||||||||
| Offering expenses | - | 420 | - | - | ||||||||||||
| Share-based compensation | 1,955 | 3,061 | 648 | 1,261 | ||||||||||||
| Non-GAAP general and administrative expenses | 13,553 | 13,112 | 4,628 | 4,450 |
